Orlandi et al., 2004 - Google Patents
The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitizationOrlandi et al., 2004
View PDF- Document ID
- 14512582313517044081
- Author
- Orlandi A
- Grasso F
- Corinti S
- Marinaro M
- Bonura A
- Boirivant M
- Colombo P
- Di Felice G
- Publication year
- Publication venue
- Clinical & Experimental Allergy
External Links
Snippet
Background Par j 1 represents the major allergenic component of Parietaria judaica pollen. Its three‐dimensional structure is stabilized by four disulphide bridges. A family of three‐ dimensional mutants of the recombinant Par j 1 (rPar j 1) allergen, showing reduced …
- 230000002009 allergen 0 title abstract description 79
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Orlandi et al. | The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization | |
| Kussebi et al. | A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy | |
| GEHLHAR et al. | Monitoring allergen immunotherapy of pollen‐allergic patients: the ratio of allergen‐specific IgG4 to IgG1 correlates with clinical outcome | |
| Ball et al. | Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy | |
| Niespodziana et al. | A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS | |
| Fellrath et al. | Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial | |
| Focke et al. | Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination | |
| Rossi et al. | Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy | |
| Focke et al. | Non‐anaphylactic surface‐exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination | |
| Freidl et al. | Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy | |
| Niederberger et al. | The allergen profile of ash (Fraxinus excelsior) pollen: cross‐reactivity with allergens from various plant species | |
| Karamloo et al. | Prevention of allergy by a recombinant multi‐allergen vaccine with reduced IgE binding and preserved T cell epitopes | |
| Asturias et al. | Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen‐specific immunotherapy | |
| Flicker et al. | Conversion of grass pollen allergen‐specific human IgE into a protective IgG1 antibody | |
| von Garnier et al. | Allergen‐derived long peptide immunotherapy down‐regulates specific IgE response and protects from anaphylaxis | |
| Bolhaar et al. | A mutant of the major apple allergen, Mal d 1, demonstrating hypo‐allergenicity in the target organ by double‐blind placebo‐controlled food challenge | |
| Wallner et al. | Allergy multivaccines created by DNA shuffling of tree pollen allergens | |
| Bonura et al. | Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family | |
| Freidl et al. | Resistance of parvalbumin to gastrointestinal digestion is required for profound and long‐lasting prophylactic oral tolerance | |
| Cook et al. | Peptide and recombinant allergen vaccines for food allergy | |
| Wiedermann et al. | Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice | |
| Wallner et al. | Recombinant allergens for pollen immunotherapy | |
| Brazhnikov et al. | Natural human Bet v 1‐specific IgG antibodies recognize non‐conformational epitopes whereas IgE reacts with conformational epitopes | |
| Niederberger et al. | Molecular approaches for new vaccines against allergy | |
| Ball et al. | Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination |